相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 克隆性:
多克隆
- 抗体英文名:
sRANK Ligand Antibody (soluble Receptor Activator of NFkB Ligand, TNFSF11, TRANCE (TNF-related activation-induced cytokine), OPGL, ODF (Osteoclast differentiation factor))
- 规格:
50 ug
产品名称:sRANK Ligand抗体|sRANK Ligand Antibody (soluble Receptor Activator of NFkB Ligand, TNFSF11, TRANCE (TNF-related activation-induced cytokine), OPGL, ODF (Osteoclast differentiation factor))
【产品形式】:艾美捷为您提供的sRANK Ligand抗体产品为溶液形式,含有50 ug抗体.该产品浓度为与批次相关,溶解于PBS(pH 7.2)缓冲液中.请在收到该sRANK Ligand抗体产品后,将其置于-20 °C冷冻保存,建议分装使用以避免反复冻融.
【背景资料】:RANKL and RANK are members of the TNF superfamily of ligands and receptors that play an important role in the regulation of specific immunity and bone turnover. RANK (receptor) was originally identified as a dendritic-cell-membrane protein, which by interacting with RANKL augments the ability of dendritic cells to stimulate naïve T-cell proliferation in a mixed lymphocyte reaction, to promote the survival of RANK + T cells, and to regulate T-cell-dependent immune response. RANKL, which is expressed in a variety of cells including osteoblasts, fibroblasts, activated T-cells and bone marrow stromal cells, is also capable of interacting with a decoy receptor called OPG. Binding of soluble OPG to sRANKL inhibits osteoclastogenesis by interrupting the signaling between stromal cells and osteoclastic progenitor cells, thereby leading to excess accumulation of bone and cartilage.
BioVision的公司总部在美丽的旧金山湾地区,它是全球生命科学公司的领导者.BioVision在开发和研究细胞凋亡检测分析、代谢检测方面具有 卓越的影响力.包括检测各种检测分析试剂盒、相关特色抗体、重组蛋白及细胞因子和酶等多种产品,以及其他创新的研究工具.其产品覆盖细胞凋亡研究、能量代 谢、细胞/组织蛋白提取、氧化应激与损伤、代谢与肥胖症、细胞增殖与毒性、信号转导、干细胞研究等领域.作为多家知名品牌的中国总代理以及中国区域代理, 艾美捷与BioVision一起为研究者们提供最好、最新的细胞生物学研究工具而不断扩大产品及服务质量.
点击:sRANK Ligand抗体,查看更详细产品说明,更多应用、储存、价格、货期等信息请致电400-6800-868垂询BioVision中国区域授权总代理艾美捷科技有限公司。
关键词:sRANK Ligand,sRANK Ligand抗体
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Receptor Binding Assay for NO-Independent Activators of Soluble Guanylate Cyclase
receptor binding assay that was successfully applied to determine the binding constant of the NO-independent activator of soluble guanylate cyclase, cinaciguat, and the impact of other small molecules on its interaction with the enzyme.
Theoretical Aspects of the Quantitative Characterization of Ligand Binding
of equilibrium responses for the interaction of the soluble domain of interleukin 6 receptor (A) with interleukin 6 immobilized on the sensor surface of a BIAcore instrument. (B ) Plot of results obtained with interleukin 6 as the competing ligand (S
【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
技术资料暂无技术资料 索取技术资料











